Wall Street Zen Upgrades BioAge Labs (NASDAQ:BIOA) to Hold

BioAge Labs (NASDAQ:BIOA) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Tuesday.

A number of other analysts have also weighed in on the stock. Citigroup upped their price target on shares of BioAge Labs from $10.00 to $15.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. Piper Sandler initiated coverage on shares of BioAge Labs in a research note on Tuesday, January 27th. They set an “overweight” rating for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of BioAge Labs in a research report on Tuesday, January 27th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $15.00.

BioAge Labs Trading Up 5.8%

Shares of BIOA opened at $20.10 on Tuesday. The stock has a 50 day moving average of $14.71 and a 200-day moving average of $8.85. BioAge Labs has a 52 week low of $2.88 and a 52 week high of $24.00. The firm has a market cap of $720.59 million, a price-to-earnings ratio of -13.22 and a beta of 1.40.

BioAge Labs (NASDAQ:BIOA) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($0.67) by $0.11. The business had revenue of $2.05 million for the quarter.

Insider Buying and Selling at BioAge Labs

In other news, insider Paul D. Rubin sold 18,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $12.00, for a total transaction of $216,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Dov A. Md Goldstein sold 27,000 shares of the stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $19.70, for a total transaction of $531,900.00. Following the sale, the chief financial officer directly owned 22,408 shares in the company, valued at approximately $441,437.60. This represents a 54.65% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 347,004 shares of company stock valued at $5,673,859 in the last 90 days. 20.82% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On BioAge Labs

Several large investors have recently bought and sold shares of BIOA. CWM LLC lifted its stake in BioAge Labs by 39.9% in the fourth quarter. CWM LLC now owns 3,693 shares of the company’s stock valued at $49,000 after buying an additional 1,053 shares during the period. Bank of America Corp DE increased its stake in BioAge Labs by 46.3% in the third quarter. Bank of America Corp DE now owns 11,119 shares of the company’s stock valued at $65,000 after purchasing an additional 3,517 shares in the last quarter. Vontobel Holding Ltd. raised its holdings in BioAge Labs by 36.4% in the third quarter. Vontobel Holding Ltd. now owns 15,000 shares of the company’s stock worth $88,000 after purchasing an additional 4,000 shares during the period. Russell Investments Group Ltd. bought a new position in shares of BioAge Labs during the third quarter worth $27,000. Finally, Strs Ohio grew its holdings in shares of BioAge Labs by 26.4% in the 4th quarter. Strs Ohio now owns 22,500 shares of the company’s stock valued at $298,000 after buying an additional 4,700 shares during the period.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.